Response to Anti-hypertensives in Pregnant and Postpartum Patients
Status:
Completed
Trial end date:
2019-04-05
Target enrollment:
Participant gender:
Summary
In this study, the investigators will evaluate the blood pressure response to nifedipine and
labetalol in pregnant and postpartum patients, who present with hypertensive disease in
pregnancy with severe range blood pressure defined as greater than 160/110. These
anti-hypertensives are first line therapy for management of severe range blood pressures in
pregnancy and postpartum by the American Congress of Obstetricians and Gynecologist (ACOG).
In addition at the Mount Sinai West site, the investigators will also analyze the ADRB1 and
similar genes involved in beta blockade, genes involved in calcium channel blockade and other
genes implicated in blood pressure response among pregnant and postpartum patients receiving
labetalol and nifedipine. This analysis will be used to determine if a pharmacogenetic
association exists between variant alleles in these receptors in the pregnant and postpartum
population.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborators:
Maimonides Medical Center Mount Sinai Hospital, New York